



NIH AIDS Reagent Program

20301 Century Boulevard
Building 6, Suite 200
Germantown, MD 20874
USA

Phone: 240 686 4740
Fax: 301 515 4015
aidsreagent.org

DATA SHEET

Reagent:	Anti-HIV-1 p24 Hybridoma (183-H12-5C)
Catalog Number:	1513
Lot Number:	160142
Release Category:	C
Provided:	1 mL of cells Post thaw cell count = 5.2×10^6 cells/mL Post thaw cell viability = 90%
Cell Type:	Balb/c mouse splenocyte x SP2-0 myeloma
Isotype:	IgG ₁ κ
Propagation Medium:	RPMI 1640, 90%; fetal bovine serum, 10%
Freeze Medium:	RPMI 1640, 40%; fetal bovine serum, 50%; DMSO, 10%
Description	This hybridoma produces a monoclonal antibody reactive with HIV-1 p24 Gag.
Special Characteristics:	This hybridoma was created by immunizing a Balb/c mouse and fusing the resulting splenocytes with SP2-O myeloma cells. The antibody produced from this hybridoma is also available (cat# 3537).
Sterility:	Negative for mycoplasma, bacteria, and fungi
Recommended Storage:	Keep the reagent in liquid nitrogen.

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.

Contributor: Dr. Bruce Chesebro and Dr. Hardy Chen

References: Toohey, K., Wehrly, K., Nishio, J., Perryman, S., & Chesebro, B. (1995). Human immunodeficiency virus envelope V1 and V2 regions influence replication efficiency in macrophages by affecting virus spread. *Virology*, 213(1), 70-79. doi:10.1006/viro.1995.1547 [PUBMED](#)

Wehrly, K., & Chesebro, B. (1997). p24 antigen capture assay for quantification of human immunodeficiency virus using readily available inexpensive reagents. *Methods*, 12(4), 288-293. doi:10.1006/meth.1997.0481 [PUBMED](#)

NOTE: Acknowledgment for publications should read "The following reagent was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: Anti-HIV-1 p24 Hybridoma (183-H12-5C) (Cat# 1513) from Dr. Bruce Chesebro." Also include the reference cited above in any publications.

Scientists at for-profit institutions or who intend commercial use of this reagent must contact the NIH Office of Technology Transfer, Email: NIAIDAIDSReagent@niaid.nih.gov, before the reagent can be released. Please specify the name and a description of the intended use of the reagent.

Last Updated November 16, 2020

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.